Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Case report

Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report

Authors: Yu Qiao, Jihong Yang, Lili Liu, Yixin Zeng, Jie Ma, Jing Jia, Li Zhang, Xiaoguang Li, Peihong Wu, Wenchao Wang, Dongge Liu, Huan Chen, Yunbo Zhao, Huan Xi, Yao Wang

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Primary hepatic angiosarcoma (PHA) is a rare and aggressive solid tumor, with high rates of local recurrence and distant metastasis, and poor prognosis. There are no established treatment guidelines for PHA.

Case presentation

A 78-year-old asymptomatic man with PHA that was successfully treated with pazopanib plus PD-1 inhibitor and RetroNectin-activated killer cells (RAK cells). After one month of treatment, there was a clear reduction in the size and number of the liver metastases; and after nearly 15 months, most of the lesions were stable, no new lesions had developed, and the side effect of treatment was minor.

Conclusion

Pazopanib, PD-1 inhibitor and RAK cells could serve as a potential option for the treatment of advanced PHA.
Literature
1.
Wang ZB, Wei LX. Primary hepatic angiosarcoma: a clinical and pathological analysis. Zhonghua Bing Li Xue Za Zhi. 2013;42(6):376–80.PubMed
2.
Timaran CH, Grandas OH, Bell JL. Hepatic angiosarcoma: long-term survival after complete surgical removal. Am Surg. 2000;66(12):1153–7.PubMed
3.
4.
Awan S, Davenport M, Portmann B, Howard ER. Angiosarcoma of the liver in children. J Pediatr Surg. 1996;31(12):1729–32.CrossRefPubMed
5.
Makk L, Delmore F, Creech JL, Ogden LL, Fadell EH, Songster CL, Clanton J, Johnson M, Christopherson WM. Clinical and morphologic features of hepatic angiosarcoma in vinyl chloride workers. Cancer. 1976;37(1):149–63.CrossRef
6.
Kim HR, Rha SY, Cheon SH, Roh JK, Park YN, Yoo NC. Clinical features and treatment outcomes of advanced stage primary hepatic angiosarcoma. Ann Oncol. 2009;20(4):780–7.CrossRefPubMed
7.
Wang ZB, Yuan J, Chen W, Wei LX. Transcription factor ERG is a specific and sensitive diagnostic marker for hepatic angiosarcoma. World J Gastroenterol. 2014;20(13):3672–9.CrossRefPubMedPubMedCentral
8.
Zheng YW, Zhang XW, Zhang JL, Hui ZZ, Du WJ LRM, Ren XB. Primary hepatic angiosarcoma and potential treatment options. J Gastroenterol Hepatol. 2014;29(5):906–11.CrossRefPubMed
9.
Orlando G, Adam R, Mirza D, Soderdahl G, Porte RJ, Paul A, Burroughs AK, Seiler CA, Colledan M, Graziadei I, et al. Hepatic hemangiosarcoma: an absolute contraindication to liver transplantation--the European liver transplant registry experience. Transplantation. 2013;95(6):872–7.CrossRefPubMed
10.
Berber E, Ari E, Herceg N, Siperstein A. Laparoscopic radiofrequency thermal ablation for unusual hepatic tumors: operative indications and outcomes. Surg Endosc. 2005;19(12):1613–7.CrossRefPubMed
11.
Gordon EM, Sankhala KK, Chawla N, Chawla SP. Trabectedin for soft tissue sarcoma: current status and future perspectives. Adv Ther. 2016;33(7):1055–71.CrossRefPubMedPubMedCentral
12.
van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schoffski P, Aglietta M, Staddon AP, Beppu Y, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–86.CrossRefPubMed
13.
Paoluzzi L, Cacavio A, Ghesani M, Karambelkar A, Rapkiewicz A, Weber J, Rosen G. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcoma Res. 2016;6:24.CrossRefPubMedPubMedCentral
14.
15.
Li W, Wang Y, Kellner DB, Zhao L, Xu L, Gao Q. Efficacy of RetroNectin-activated cytokine-induced killer cell therapy in the treatment of advanced hepatocelluar carcinoma. Oncol Lett. 2016;12(1):707–14.CrossRefPubMedPubMedCentral
16.
Ma H, Zhang Y, Wang Q, Li Y, He J, Wang H, Sun J, Pan K, Chen M, Xia J. Therapeutic safety and effects of adjuvant autologous RetroNectin activated killer cell immunotherapy for patients with primary hepatocellular carcinoma after radiofrequency ablation. Cancer Biol Ther. 2010;9(11):903–7.CrossRefPubMed
17.
Han L, Shang YM, Song YP, Gao QL. Biological character of RetroNectin activated cytokine-induced killer cells. J Immunol Res. 2016;2016:5706814.PubMedPubMedCentral
18.
Lee HJ, Lee YS, Kim HS, Kim YK, Kim JH, Jeon SH, Lee HW, Kim S, Miyoshi H, Chung HM, et al. Retronectin enhances lentivirus-mediated gene delivery into hematopoietic progenitor cells. Biologicals. 2009;37(4):203–9.CrossRefPubMed
19.
Inagaki A, Ishida T, Ishii T, Komatsu H, Iida S, Ding J, Yonekura K, Takeuchi S, Takatsuka Y, Utsunomiya A, et al. Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factors. Int J Cancer. 2006;118(12):3054–61.CrossRefPubMed
Metadata
Title
Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report
Authors
Yu Qiao
Jihong Yang
Lili Liu
Yixin Zeng
Jie Ma
Jing Jia
Li Zhang
Xiaoguang Li
Peihong Wu
Wenchao Wang
Dongge Liu
Huan Chen
Yunbo Zhao
Huan Xi
Yao Wang
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-3996-3

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Research article

A novel combined systemic inflammation-based score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolization

Research article

Acyclic retinoid and angiotensin-II receptor blocker exert a combined protective effect against diethylnitrosamine-induced hepatocarcinogenesis in diabetic OLETF rats

Research article

Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy

Research article

MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-κB

Case report

Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation

Research article

A 35-gene signature discriminates between rapidly- and slowly-progressing glioblastoma multiforme and predicts survival in known subtypes of the cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits